Please login to the form below
respiratory syncytial virus
This page shows the latest respiratory syncytial virus news and features for those working in and with pharma, biotech and healthcare.
Enanta takes legal action against Pfizer over Paxlovid patent infringement
Among these drugs, Enanta has produced therapies to address respiratory syncytial virus (RSV), human metapneumovirus (hMPV) chronic hepatitis B virus (HBV) and focused R&D efforts for COVID-19 early into
Latest news
-
Moderna to launch Innovation and Technology Center in the UK
UK. Throughout the COVID-19 pandemic, Moderna worked with governments, healthcare professionals and other key stakeholders to help combat the virus and future pathogens. ... The company, with the support of the UK government, plans to use the site to
-
Pfizer and viral infection specialist ReViral agree on $525m deal
A private biopharma company, ReViral focuses on the discovery, development and commercialisation of antiviral therapeutics that are designed to target respiratory syncytial virus (RSV). ... RSV. ReViral has a portfolio of promising therapeutic candidates,
-
Pfizer receives Breakthrough Therapy Designation from FDA for RSV vaccine candidate
Pfizer has announced that the US Food and Drug Administration (FDA) has granted its respiratory syncytial virus (RSV) vaccine candidate a Breakthrough Therapy Designation. ... RSV is a contagious virus and is a common cause of respiratory illness, with
-
AstraZeneca blocks take-private buyout of Sobi
Sobi. This came about through a 2018 deal that saw Sobi gain the rights to sell AZ’s respiratory drug Synagis in the US. ... Synagis prevents serious lower respiratory tract infections caused by the respiratory syncytial virus in infants and young
-
Janssen’s RSV vaccine provides high protection against respiratory infections
Janssen, owned by Johnson &Johnson, has announced that its investigational respiratory syncytial virus (RSV) vaccine candidate is highly efficacious in protecting against lower respiratory tract disease caused by RSV. ... Respiratory syncytial virus is a
More from news
Approximately 5 fully matching, plus 45 partially matching documents found.
Latest Intelligence
-
Well-funded life sciences firms are making long-term progress – and their investors are too
Up to that point, the drug was being developed to treat respiratory viral infections in patients with COPD who are at risk of experiencing exacerbations, which can be deadly and typically ... challenge study, in this case respiratory syncytial virus (RSV)
-
COVID-19: the race to find a vaccine
In the absence of a knockout antiviral, researchers are trying to mitigate harmful effects of the virus. ... Scientists have since industrialised the concept, leading to the development of antibodies against Ebola and respiratory syncytial virus.
-
Getting multichannel marketing right
has encouraged people to knit hats and blankets for babies to alert people to respiratory syncytial virus.
-
Deal Watch March 2017
In order to focus its respiratory resources on products such as Symbicort and benralizumab, AstraZeneca has agreed that its product Tudorza (marketed for COPD) and Duaklir (in phase III for COPD) ... Headline. $m. AstraZeneca/ MedImmune. Sanofi Pasteur.
-
Pharma deals during September 2014
Alios has an oral anti-viral in phase 2 for treatment of infant respiratory syncytial virus (RSV) which complements J&J's early stage programmes in RSV.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Dutch biotech Mucosis promotes Thomas Johnston to CEO
During the last 12 months Mucosis has completed a clinical proof of concept study in human influenza for Mimopath and advanced respiratory syncytial virus (RSV) candidate SynGEM into pre-clinical studies.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Biogen and Happify Health team up to create digital platform for MS patients
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Moderna to launch Innovation and Technology Center in the UK
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Novo Nordisk and Echosens collaborate to advance early diagnosis of non-alcoholic steatohepatitis
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- How pharma found its voice – health communications for a brave new world
- The importance of beliefs in creative health engagement
- In recognition of the Anniversary of Stonewall, Nucleus Global brings attention and awareness to persistent health care inequities experienced by LGBTQIA+
- Novo Nordisk and Echosens collaborate to advance early diagnosis of non-alcoholic steatohepatitis
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Almirall shares positive topline results from atopic dermatitis trials
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Pfizer to buy 8.1% stake in Valneva in support of joint Lyme disease programme
- Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease
Latest intelligence
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
- Report: Omnichannel advice for the life science industry
- In the latest issue of Delta magazine, Fishawack Health's Medical, Marketing, and Consulting experts share their practical advice for creating meaningful omnichannel stakeholder experiences and reveal our proprietary tool for...
